UnknownPhase 2NCT05324384
Different Doses of Sirolimus for the Maintenance Treatment of Kaposiform Hemangioendothelioma
Studying Kaposiform hemangioendothelioma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- West China Hospital
- Principal Investigator
- Yi Ji, MD, PhD, MSW, LICSWWest China Hospital
- Intervention
- Sirolimus(drug)
- Enrollment
- 30 target
- Eligibility
- 14 years · All sexes
- Timeline
- 2022 – 2025
Study locations (1)
- West China Hospital of Sichuan University, Chengdu, Sichuan, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05324384 on ClinicalTrials.govOther trials for Kaposiform hemangioendothelioma
Additional recruiting or active studies for the same condition.